FDA: early efforts to prepare new drug labels ‘not as good as we’d hoped’

"Not as good as we'd hoped" is the reaction by the FDA to early efforts by manufacturers to prepare Rx drug labels in conformance with the agency's new "content and format" requirements, in effect since publication of a final rule on the subject last summer.

James G. Dickinson

November 1, 2006

5:00 am

“Not as good as we’d hoped” is the reaction by the FDA to early efforts by manufacturers to prepare Rx drug labels in conformance with the agency’s new “content and format” requirements, in effect since publication of a final rule on the subject last summer.

From the November 01, 2006 Issue of MM+M - Medical Marketing and Media

From Our Partners

HUB services, patient engagement, and specialty pharmacy: One patient support ecosystem with three core components

Partner Content

HUB services, patient engagement, and specialty pharmacy: One patient support ecosystem with three core components

The evolution of patient needs and rising consumer expectations are shaping a new era in healthcare — one that calls for a paradigm shift in the pharmaceutical industry's approach to patient support.

Omnichannel activation without omniburden

Partner Content

Omnichannel activation without omniburden

Explore solutions for practically implementing omnichannel approaches into your go-to-market activation.

Taking a patient-centric approach to privacy

Partner Content

Taking a patient-centric approach to privacy

This podcast will explore ways to deliver tailored content that activates, educates and empowers patients while prioritizing privacy and consent.

Living brands: How to build brands in the age of omnichannel

Partner Content

Living brands: How to build brands in the age of omnichannel

This podcast looks at how to leverage advancements in data, technology, AI and content development in order to become a Living Brand.